Breaking News on Global Pharmaceutical Technology & Manufacturing

News in brief

Aeropharm selects Prosonix for crystallisation

16-Dec-2008

Related topics: Processing equipment, Ingredients

 

German inhaled drug specialist Aeropharm will use Prosonix’ sonocrystallisation technology to develop generics in its candidate pipeline.

 

 

The Rudolstadt-headquartered firm said that Prosonix’ unique crystallisation approach produces optimally-sized active pharmaceutical ingredient (API) particles direct from solution, bypassing destructive processes like milling and micronization that are used in traditional manufacture.

 

 

 

Aeropharm is targeting the lucrative inhaled drug market, which is expected to be worth $38bn in 2012. In particular the firm is focused on the development of “difficult-to-make” generic products.

Copyright - Unless otherwise stated all contents of this web site are © 2012 - William Reed Business Media SAS - All Rights Reserved - For permission to reproduce any contents of this web site, please email our Syndication department copyright@wrbm.com - Full details for the use of materials on this site can be found in the Terms & Conditions

© 2012 - William Reed Business Media SAS - All rights reserved.